Meissa Vaccines, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2014-01-01
- Employees
- 11
- Market Cap
- -
Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months
Phase 1
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- Biological: Investigational RSV vaccine MV-012-968 (Dosage 2)Biological: Investigational RSV vaccine MV-012-968 (Dosage 1)Biological: Investigational RSV vaccine MV-012-968 (Dosage 3; single-dose)Biological: Investigational RSV vaccine MV-012-968 (Dosage 3; two-dose)Other: Placebo (single-dose)Other: Placebo (two-dose)
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2022-08-02
- Lead Sponsor
- Meissa Vaccines, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT04909021
- Locations
- 🇺🇸
Clinical Research Prime, Idaho Falls, Idaho, United States
🇺🇸Coastal Pediatric Research, Summerville, South Carolina, United States
🇺🇸Benchmark Research, San Antonio, Texas, United States
Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults
Phase 1
- Conditions
- Covid19
- Interventions
- Biological: Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Two Doses, Intranasal DropsBiological: Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal SprayBiological: Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 1, Single Dose, Intranasal DropsBiological: Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 2, Single Dose, Intranasal DropsBiological: Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Drops
- First Posted Date
- 2021-03-15
- Last Posted Date
- 2022-08-02
- Lead Sponsor
- Meissa Vaccines, Inc.
- Target Recruit Count
- 130
- Registration Number
- NCT04798001
- Locations
- 🇺🇸
Wake Research, Raleigh, North Carolina, United States
🇺🇸Johnson County Clin-Trials, Lenexa, Kansas, United States
Human Challenge Study to Evaluate the Efficacy of MV-012-968 Vaccine
Phase 2
Completed
- Conditions
- RSV Infection
- Interventions
- Other: PlaceboBiological: MV-012-968
- First Posted Date
- 2020-12-30
- Last Posted Date
- 2022-08-04
- Lead Sponsor
- Meissa Vaccines, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT04690335
- Locations
- 🇬🇧
hVIVO Services Ltd, London, United Kingdom
Study of the Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seropositive Children
Phase 1
Completed
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Other: PlaceboBiological: Investigational RSV vaccine MV-012-968 (Dosage 1)Biological: Investigational RSV vaccine MV-012-968 (Dosage 2)Biological: Investigational RSV vaccine MV-012-968 (Dosage 3)
- First Posted Date
- 2020-06-23
- Last Posted Date
- 2021-06-29
- Lead Sponsor
- Meissa Vaccines, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT04444284
- Locations
- 🇺🇸
Meridian Clinical Research, Omaha, Nebraska, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Safety and Immune Response to an Investigational Vaccine Against Respiratory Syncytial Virus in Healthy Adults
Phase 1
Completed
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Biological: RSV vaccine MV-012-968 (dosage #1)Biological: RSV vaccine MV-012-968 (dosage #2)
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Meissa Vaccines, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04227210
- Locations
- 🇺🇸
Johnson County Clin-Trials, Lenexa, Kansas, United States
© Copyright 2025. All Rights Reserved by MedPath